在接受低甲基化剂 (HMAs) 的抗炎性贫血与过量爆发 (RAEB) 患者的临床结果
Amer M Zeidan1, Elizabeth S Mearns2, Carmen D Ng2
1Department of Internal Medicine, Section of Hematology, Yale University School of Medicine and Yale Cancer Center, New Haven, CT.
Clinical lymphoma, myeloma & leukemia
|November 23, 2023
概括
在现实世界中,阿扎西提丁 (AZA) 和达西 (DEC) 用于高风险的骨髓分裂综合征,这两种低甲基化剂 (HMA) 之间没有显著差异. 患者的结局比临床试验更短,表明需要进一步研究.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床研究 临床研究
背景情况:
- 具有过多弹性耐火性贫血 (RAEB) 是一种高风险的骨髓质疏松症候群/新生瘤形式.
- 低甲基化剂 (HMA) 如阿扎丁 (AZA) 和达西 (DEC) 用于RAEB治疗.
- 了解HMAs在现实世界的有效性至关重要.
研究的目的:
- 评估RAEB患者在现实环境中的AZA和DEC的临床有效性.
- 为了比较AZA和DEC之间的整体存活率 (OS),无事件存活率 (EFS) 和急性髓性白血病 (AML) 进展率.
- 为了确定临床试验结果和真实世界患者数据之间的差异.
主要方法:
- 利用SEER-Medicare数据库 (2009-2017年) 对被诊断患有RAEB的66岁以上的患者.
- 包括接受AZA或DEC作为第一线治疗的患者.
- 测量了OS,EFS和AML进展的发生率.
主要成果:
- 在973名患者中,75.8%接受了AZA,24.2%接受了DEC.
- 中位数OS为13.9个月,中位数EFS为5.2个月.
- 在AZA和DEC之间没有观察到临床益处的显著差异.
结论:
- 接受AZA或DEC治疗的RAEB患者的现实结果比AZA-001临床试验中报告的结果要短.
- 临床和现实环境之间的差异需要进一步调查.
- 需要进一步的研究来了解这些结果变化的原因.
相关概念视频
Bone Marrow Sampling and Transplants
334
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
334
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K


